ClinicalTrials.gov
ClinicalTrials.gov Menu

Quantitative Estimation of Thrombus Burden in Patients With STEMI Using Micro-Computed Tomography (QUEST-STEMI) (QUEST-STEMI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03429608
Recruitment Status : Recruiting
First Posted : February 12, 2018
Last Update Posted : February 12, 2018
Sponsor:
Collaborators:
Hellenic Centre for Marine Research
Harvard Medical School
MHAT Hadji Dimitar Hospital, Sliven, Bulgaria
Information provided by (Responsible Party):
Karagiannidis Efstratios, Aristotle University Of Thessaloniki

Brief Summary:

The study aims to assess for the first time, through the application of innovative technologies (micro-CT), important characteristics of aspirated thrombi (such as their volume and their density), which might be linked to certain clinical outcomes, in patients presenting with STEMI and referred for primary Percutaneous Coronary Intervention (PCI). To this end, a methodology for the exact estimation of thrombus burden by measuring the volume and the density of aspirated thrombi will be developed. After being aspirated using dedicated catheters, thrombi will be preserved in formalin and their volume and their density will be calculated with the use of micro-CT. Having a better resolution than conventional computed tomography, micro-CT will allow us to create 3D models of aspirated thrombi from a series of x-ray projection images. These 3D models will be further analyzed in order to find the volume and the density of aspirated thrombi. Shape analysis of the surface of aspirated thrombi and potential differences in their structure will also be assessed. Correlation of these variables with clinical parameters and angiographic outcomes will be attempted.

Thus, a risk-stratification model will be developed combining:

  • Clinical and laboratory data,
  • Angiographic parameters,
  • Data regarding the volume, the density and the composition of aspirated thrombi.

This model will enable the stratification of the cardiovascular and cerebrovascular risk of patients and the identification of who will benefit from thrombus aspiration, providing a personalized approach in treating patients with STEMI.


Condition or disease
ST Elevation Myocardial Infarction Thrombi

Detailed Description:

Acute myocardial infarction with ST elevation (STEMI) remains one of the leading causes of mortality in developed countries, in spite of the important advances in pharmacological therapy and in mechanical reperfusion therapy. Having an important role in provoking ischemia, thrombus has been studied in many clinical trials and high thrombus burden has been proven to be an independent risk factor for stent thrombosis and for Major Adverse Clinical outcomes. However large randomized controlled trials concerning thrombus aspiration showed controversial results, providing as a whole no evidence of distinct benefits for thrombus aspiration. A possible explanation could be that aspiration was performed as a routine strategy in all of these trials, whereas these patients should be considered as a heterogeneous group and thus they should be risk-stratified. For this reason, it is of paramount importance to classify patients according to the volume of thrombus burden. The currently existing classifications of thrombus burden (the most important being those of Gibson and of Sianos) are based on visual assessment of angiographic characteristics and thus they are not reflecting the volume of the thrombi in actual, absolute numbers.

The main purpose of the study is to develop a methodology for the exact estimation of thrombus burden by measuring the volume and the density of aspirated thrombi in patients presenting with STEMI and referred for primary PCI. After being aspirated using dedicated catheters, thrombi will be preserved in formalin and their volume will be calculated with the use of micro-CT. The scanning procedure results into a series of projection images arranged in the form of image stacks which, in turn, are reformed in sections (cross section images) with the use of the NRecon (Bruker, Kontich, Belgium) software, which applies a modified algorithm of backward projection Feldkamp. The resulting sections will be combined to create the 3D models which will be further analyzed to extract useful measurements for the characteristics of the thrombi, such as for the volume and the elative density. Shape analysis on the surface and internal structure of the three-dimensional representations of the specimens will lead to the identification of the important features that can be used to estimate variability within samples and perform clustering for the significant differences between clots. In addition, possible differences in clot internal and external structure (e.g. architecture of the various cell types) will be assessed through the 3D models rendered from the stacks of images The Secondary end points of the study include the examination of the association of the aforementioned variables with the angiographic classification of thrombus burden (according to Sianos), with electrocardiographic and angiographic characteristics suggestive of poor patient prognosis and with major adverse cardiac events during the follow-up period of one year.

This method could become the gold standard for the exact measurement of thrombus burden and could be used in larger, clinically-oriented trials to help stratify patients with thrombus burden according to their risk for adverse outcomes.


Study Type : Observational
Estimated Enrollment : 70 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Quantitative Estimation of Thrombus Burden in Patients With ST Elevation Acute Myocardial Infarction (STEMI) With the Use of Micro-computed Tomography-A Methodological Approach (QUEST-STEMI)
Actual Study Start Date : January 25, 2018
Estimated Primary Completion Date : January 2021
Estimated Study Completion Date : January 2021

Resource links provided by the National Library of Medicine


Group/Cohort
patients with low thrombus burden
patients with the lower volume of aspirated thrombi, as measured using micro-CT
patients with high thrombus burden
patients with the higher volume of aspirated thrombi, as measured using micro-CT



Primary Outcome Measures :
  1. volume of aspirated thrombus burden [ Time Frame: 12 months ]
    The volume of aspirated thrombi will be quantified using micro-CT.

  2. density of aspirated thrombus burden [ Time Frame: 12 months ]
    The density of aspirated thrombi will be quantified using micro-CT.

  3. MACCE-free survival [ Time Frame: 12 months ]
    Time between the date of diagnosis and MACCE during the follow-up period of 12 months. MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.


Secondary Outcome Measures :
  1. association between thrombus volume with factors from patients medical history [ Time Frame: 12 months ]
    Potential association of thrombus volume (as assessed using micro-ct) with factors potentially affecting thrombus burden, including history of diabetes mellitus (dichotomous variable yes/no), use of antiplatelet drugs or anticoagulants (dichotomous variable yes/no),pain-to-balloon time (in minutes) and history of smoking (dichotomous variable yes/no) will be explored and reported.

  2. association between thrombus density with factors from patients medical history [ Time Frame: 12 months ]
    Potential association of thrombus density ( as assessed using micro-CT) with factors potentially affecting thrombus burden, including history of diabetes mellitus (dichotomous variable yes/no), use of antiplatelet drugs or anticoagulants (dichotomous variable yes/no),pain-to-balloon time (in minutes) and history of smoking (dichotomous variable yes/no) will be explored and reported.

  3. Correlation of the volume of aspirated thrombus burden with the Sianos' classification of thrombus burden [ Time Frame: 12 months ]
    Potential correlation of the volume of aspirated thrombus burden, as assessed using the micro-CT and the angiographic classification of thrombus burden according to Sianos will be explored. According to Sianos' classification thrombi are classified in the following categories: G0,G1,G2,G3,G4.

  4. Correlation of thrombus density with the Sianos' classification of thrombus burden [ Time Frame: 12 months ]
    Potential correlation of thrombus density, as assessed using the micro-CT and the angiographic classification of thrombus burden according to Sianos will be explored.

  5. association of thrombus volume with electrocardiographic outcomes suggestive of poor patient prognosis [ Time Frame: 12 months ]
    Potential association of thrombus volume as measured using micro-CT with ST segment resolution will be explored. ST resolution will be classified as complete (>70%), partial (30-70%), or absent (<30%).

  6. association of thrombus density with electrocardiographic outcomes suggestive of poor patient prognosis [ Time Frame: 12 months ]
    Potential association of thrombus density as measured using micro-CT with ST segment resolution will be explored. ST resolution will be classified as complete (>70%), partial (30-70%), or absent (<30%).

  7. association of thrombus volume with post-procedural Thrombolysis in Myocardial Infarction(TIMI) flow [ Time Frame: 12 months ]
    Potential association of thrombus volume as measured using micro-CT, with post-procedural TIMI flow (classified as previously described: TIMI flow 0,1,2 or 3) will be explored

  8. association of thrombus density with post-procedural TIMI flow [ Time Frame: 12 months ]
    Potential association of thrombus density as measured using micro-CT, with post-procedural TIMI flow (classified as previously described: TIMI flow 0,1,2 or 3) will be explored

  9. association of thrombus volume with myocardial blush grade [ Time Frame: 12 months ]
    Potential association of thrombus volume as measured using micro-CT, with myocardial blush grade (classified as previously described: myocardial blush grade 0, myocardial blush grade 1, myocardial blush grade 2 and myocardial blush grade 3) will be explored.

  10. association of thrombus density with myocardial blush grade [ Time Frame: 12 months ]
    Potential association of thrombus density as measured using micro-CT, with myocardial blush grade (classified as previously described: myocardial blush grade 0, myocardial blush grade 1, myocardial blush grade 2 and myocardial blush grade 3) will be explored.

  11. association of thrombus volume with distal embolization . [ Time Frame: 12 months ]
    Potential association of thrombus volume as measured using micro-CT, with distal embolization (dichotomous variable yes/no) will be explored.

  12. association of thrombus density with distal embolization . [ Time Frame: 12 months ]
    Potential association of thrombus density as measured using micro-CT, with distal embolization (dichotomous variable yes/no) will be explored.

  13. association of thrombus volume with Major Adverse Cardiac and Cerebrovascular Events (MACCE) [ Time Frame: 12 months ]
    Potential association of thrombus volume, as measured using micro-CT with MACCE during the follow-up period of 12 months, will be explored. MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.

  14. association of thrombus density with Major Adverse Cardiac and Cerebrovascular Events (MACCE) [ Time Frame: 12 months ]
    Potential association of thrombus density, as measured using micro-CT with MACCE during the follow-up period of 12 months, will be explored. MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.


Biospecimen Retention:   Samples Without DNA
aspirated thrombi from patients with ST elevation myocardial infarction, who undergo primary PCI and thrombus aspiration


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
consecutive patients presenting with ST elevation myocardial infarction, who undergo primary PCI and thrombus aspiration
Criteria

Inclusion Criteria:

  • Patients presenting with symptoms of myocardial ischemia lasting for more than 30 minutes
  • Definite ECG changes indicating STEMI
  • Patients undergoing primary PCI within 12 hours from symptom onset
  • Possibility to perform thrombus aspiration
  • Age>18 years
  • Written informed consent prior to enrolment in the clinical trial

Exclusion Criteria:

  • Treatment with fibrinolytic therapy for qualifying index STEMI event
  • Patients with known intolerance to aspirin, ticagrelor or heparin
  • Patients with active internal bleeding
  • Patients with a recent history of intracranial hemorrhage

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03429608


Contacts
Contact: Efstratios Karagiannidis, MD,MSc 6938943309 ext 0030 stratoskarag@gmail.com

Locations
Greece
University General Hospital of Thessaloniki AHEPA Recruiting
Thessaloníki, Greece, 54636
Contact: Efstratios Karagiannidis, MD,MSc    6938943309 ext 0030    stratoskarag@gmail.com   
Principal Investigator: Efstratios Karagiannidis, MD,MSc         
Sponsors and Collaborators
Aristotle University Of Thessaloniki
Hellenic Centre for Marine Research
Harvard Medical School
MHAT Hadji Dimitar Hospital, Sliven, Bulgaria
Investigators
Study Chair: Georgios Sianos, MD,PhD, FESC Associate Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki
Principal Investigator: Efstratios Karagiannidis, MD,MSc Phd candidate, Aristotle University of Thessaloniki
Principal Investigator: Charalambos Karvounis, MD,Phd Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki
Principal Investigator: George Giannakoulas, MD,Phd Assistant Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki
Principal Investigator: Christos Arvanitidis, Phd Director of Research, Hellenic Center for Marine Research
Principal Investigator: Ioannis Vizirianakis, PharmD, PhD Associate Professor, School of Pharmacy, Aristotle University of Thessaloniki
Principal Investigator: James S Michaelson, MD,Phd Associate Professor, Department of Pathology, Harvard Medical School
Principal Investigator: Kleoniki Keklikoglou, MSc Hellenic Center for Marine Research
Principal Investigator: Ivelin Samra, MD Head of cardiology department at MHAT"Hadzy Dimityr" Sliven
Principal Investigator: Nikolaos Konstantinidis, MD,MSc Phd candidate, Aristotle University of Thessaloniki
Principal Investigator: Georgios Sofidis, MD,Phd Aristotle University Of Thessaloniki

Publications:
Responsible Party: Karagiannidis Efstratios, MD, MSc, Phd candidate, Aristotle University Of Thessaloniki
ClinicalTrials.gov Identifier: NCT03429608     History of Changes
Other Study ID Numbers: 20170210
First Posted: February 12, 2018    Key Record Dates
Last Update Posted: February 12, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: The decision to share or not individual participant data with other researchers will depend on the purpose and the scope of the proposed research

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Infarction
Myocardial Infarction
ST Elevation Myocardial Infarction
Thrombosis
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Embolism and Thrombosis